A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

Table 5 Prognostic factors. Cox regression analysis for patients' survival.

	Univariate			Multivariate
	HR	95% CI	P	HR	95% CI	P
Age
< = 65	1	-	-
> 65	0.83	0.57-1.21	0.329
Performance status
0	1	-	-	1	-	-
1-2	1.96	1.32-2.90	0.001	1.89	1.25-2.88	0.003
Previous exposure to taxanes
No	1	-	-
Yes	1.18	0.62-2.27	0.610
Disease status
Non-measurable	1	-	-
Measurable	1.49	0.88-2.55	0.141
Platinum-free interval
6-12 months	1	-	-	1	-	-
12.1-24 months	0.58	0.37-0.89	0.013	0.54	0.34-0.86	0.009
> 24 months	0.37	0.22-0.61	< 0.001	0.36	0.21-0.61	< 0.001
Randomization group
A	1	-	-	1	-	-
B	1.15	0.78-1.66	0.455	1.19	0.80-1.76	0.399

ISSN: 1741-7015